NUS Links:
Pancreatic cancer is a devastating illness with a poor five-year survival rate. A team of researchers, which includes A/Prof Gautam Sethi, explores the role of autophagy in pancreatic cancer and
5-Fluorouracil (5-FU) is a common chemotherapy drug widely used around the world to treat cancer but development of resistance which compromises responsiveness remains a major hurdle to its efficacy. A
A team of researchers, led by A/Prof Gautam Sethi from N2CR, conducted a study investigating the therapeutic possibilities of berberine, a natural compound, for breast cancer. Their findings revealed that
Osteosarcoma, the most common bone cancer, usually affects children or adolescents during their pubertal growth spurt. Prognosis is poor for patients with advanced osteosarcoma, with low overall survival rates and
Epstein-Barr virus (EBV)-associated smooth muscle tumours (EBV-SMTs) are rare tumours that can arise in immunosuppressed patients. Such patients include those who are post-transplant or have HIV/AIDS or congenital immunodeficiency. However,
Different combinations of oncogene activation in cancer cells can affect patient outcomes. Specifically, in this study led by N2CR member Dr Anand Jeyasekharan, the authors looked at a type of
Mutations affecting p53 are amongst the commonest genetic alterations in human cancer. Mutant p53 proteins are thought to promote carcinogenesis either by inactivating p53’s cancer-suppressing functions, or instead, by acquiring
A/Prof Polly Chen has been identified as an Asian RNA Research Ambassador by the RNA Society. Listen to her speak about her interest and career in science.
This comprehensive review describes the various therapeutic interventions using plant‐derived natural products and their semi‐synthetic derivatives, with nano-formulations that promises to be used as EMT blockers in the clinic. Read
The accurate diagnosis of the most common small B-cell lymphoma histological subtypes can pose a significant challenge for pathologists. There is an urgent need to address this challenge as the